넥타테라퓨틱스 (NKTR)

02:54 AM

Nektar Therapeutics Shares Rise After Upgrade From Oppenheimer -March 14, 2025 at 02:54 pm EDT - Marketscreener.com

02:54 AM

10:28 AM

Nektar stock upgraded at Oppenheimer (NKTR:NASDAQ) - Seeking Alpha

10:28 AM

08:10 AM

Nektar Therapeutics (NASDAQ:NKTR) Q4 2024 Earnings Call Transcript - Insider Monkey

08:10 AM

07:40 AM

Oppenheimer Upgrades Nektar Therapeutics (NKTR) to Outperform - StreetInsider.com

07:40 AM

07:33 AM

Nektar Therapeutics (NKTR) Q4 Earnings Miss Estimates (Revised) - Yahoo Finance

07:33 AM

07:24 AM

Oppenheimer Upgrades Nektar Therapeutics to Outperform From Market Perform, Price Target is $6 - Marketscreener.com

07:24 AM

06:23 AM

Nektar Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance

06:23 AM

Mar 13, 2025

Nektar Therapeutics’ Earnings Call: Optimism Amid Challenges - TipRanks

Mar 13, 2025

Mar 13, 2025

BTIG keeps Nektar stock Neutral with $4.00 target By Investing.com - Investing.com Australia

Mar 13, 2025

Mar 13, 2025

Promising Pipeline and Strategic Positioning: Julian Harrison’s Buy Rating on Nektar Therapeutics - TipRanks

Mar 13, 2025

Mar 13, 2025

Nektar Q4 Loss Wider Than Expected, Pipeline in Focus, Stock Up - Yahoo Finance

Mar 13, 2025

Mar 13, 2025

Nektar Therapeutics: Poised for Growth with Promising Rezpeg Study and Market Potential - TipRanks

Mar 13, 2025

Mar 13, 2025

Assessing Nektar Therapeutics: Insights From 4 Financial Analysts - Benzinga

Mar 13, 2025

Mar 13, 2025

BTIG keeps Nektar stock Neutral with $4.00 target - Investing.com India

Mar 13, 2025

Mar 13, 2025

Jefferies cuts Nektar stock target to $1.00, maintains hold - Investing.com India

Mar 13, 2025

Mar 13, 2025

Nektar Therapeutics (NKTR) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial ... - Yahoo Finance

Mar 13, 2025

Mar 13, 2025

Nektar Therapeutics (NKTR) Q4 2024 Earnings Call Highlights: Str - GuruFocus.com

Mar 13, 2025

Mar 12, 2025

Nektar Therapeutics Reports 2024 Financial Progress - TipRanks

Mar 12, 2025

Mar 12, 2025

Nektar reports Q4 adjusted EPS (15c), consensus (19c) - TipRanks

Mar 12, 2025

Mar 12, 2025

Nektar: Q4 Earnings Snapshot - San Antonio Express-News

Mar 12, 2025

Mar 12, 2025

Nektar Therapeutics (NKTR) Q4 Earnings Beat Estimates - Yahoo Finance

Mar 12, 2025

Mar 12, 2025

NEKTAR THERAPEUTICS Earnings Results: $NKTR Reports Quarterly Earnings - Nasdaq

Mar 12, 2025

Mar 12, 2025

Earnings call transcript: Nektar Therapeutics’ Q4 2024 beats EPS expectations, stock surges - Investing.com India

Mar 12, 2025

Mar 12, 2025

Nektar: Q4 Earnings Snapshot -March 12, 2025 at 06:13 pm EDT - Marketscreener.com

Mar 12, 2025

Mar 12, 2025

Nektar Therapeutics reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 12, 2025

Mar 12, 2025

Nektar Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results - Longview News-Journal

Mar 12, 2025

Mar 12, 2025

Nektar Therapeutics shares rise on Q4 earnings beat By Investing.com - Investing.com Australia

Mar 12, 2025

Mar 12, 2025

Nektar Therapeutics shares rise on Q4 earnings beat - Investing.com India

Mar 12, 2025

Mar 12, 2025

Nektar Therapeutics (NKTR) Tops Q4 EPS by 19c - StreetInsider.com

Mar 12, 2025

Mar 12, 2025

Alopecia Areata Market to Expand Significantly by 2032, States DelveInsight Report | Pfizer, Suzhou Zelgen Biopharma, Eli Lilly/ Incyte, Throne Biotech, Legacy Healthcare - Barchart

Mar 12, 2025

Mar 08, 2025

Nektar Therapeutics (NASDAQ:NKTR) Receives $4.08 Consensus PT from Brokerages - Defense World

Mar 08, 2025

Mar 07, 2025

AstraZeneca selects Daiichi Sankyo as US marketing partner for Movantik - FirstWord Pharma

Mar 07, 2025

Mar 07, 2025

AstraZeneca, Nektar's Moventig recommended for approval in Europe - FirstWord Pharma

Mar 07, 2025

Mar 07, 2025

Nektar Therapeutics to Host Earnings Call - ACCESS Newswire

Mar 07, 2025

Mar 05, 2025

Want Direct Insights from Nektar's CEO? Q4 Earnings Call Will Reveal 2024's Full Picture - StockTitan

Mar 05, 2025

Mar 05, 2025

Metastatic Melanoma Pipeline 2024: Key Companies, MOA, ROA, - openPR

Mar 05, 2025

Mar 05, 2025

Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2024 on Wednesday, March 12, 2025, After Close of U.S.-Based Financial Markets - Blue Mountain Eagle

Mar 05, 2025

Mar 01, 2025

Nektar completes enrolment in trial of rezpegaldesleukin for alopecia areata - MSN

Mar 01, 2025

Mar 01, 2025

HC Wainwright Reiterates Buy Rating for Nektar Therapeutics (NASDAQ:NKTR) - MarketBeat

Mar 01, 2025

Mar 01, 2025

Nektar Therapeutics (NKTR) Expected to Announce Earnings on Monday - Defense World

Mar 01, 2025

Feb 28, 2025

Nektar Therapeutics (NASDAQ:NKTR) Receives "Market Perform" Rating from William Blair - MarketBeat

Feb 28, 2025

Feb 28, 2025

Bambusa Therapeutics doses first volunteers in Phase I bispecific AD trial - Yahoo Finance

Feb 28, 2025

Feb 28, 2025

Investor Network: Nektar Therapeutics to Host Earnings Call - ACCESS Newswire

Feb 28, 2025

Feb 26, 2025

Nektar completes enrollment for alopecia study of rezpegaldesleukin By Investing.com - Investing.com South Africa

Feb 26, 2025

Feb 26, 2025

Nektar completes enrollment for alopecia study of rezpegaldesleukin - Investing.com India

Feb 26, 2025

Feb 26, 2025

Nektar Therapeutics (NKTR) Announces Completion of Target Enrollment in REZOLVE-AA Phase 2b Clinical Trial of Rezpegaldesleukin - StreetInsider.com

Feb 26, 2025

Feb 26, 2025

Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AA Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Severe-to-Very Severe Alopecia Areata - Longview News-Journal

Feb 26, 2025

Feb 25, 2025

Buy Rating for Nektar Therapeutics: Strategic Collaboration with TrialNet Enhances Rezpeg’s Potential in Type 1 Diabetes - TipRanks

Feb 25, 2025

Feb 25, 2025

H.C. Wainwright maintains $6.50 target on Nektar stock By Investing.com - Investing.com Canada

Feb 25, 2025

Feb 25, 2025

H.C. Wainwright maintains $6.50 target on Nektar stock - Investing.com India

Feb 25, 2025